Concordantly, a recent study suggested that the targeted depletion of CXCL12 specifically from mesenchymal stromal cells (MSC) promoted CML LSC self-renewal, including in the presence of a TKI, while reducing the number of normal HSC. The gene discussed is CXCL12; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.